Veronica Richardson, ANP-BC, DCNP, and Marc Serota, MD, discuss his thoughts on Acute Versus Chronic Urticaria on Friday, November 3, 2022, at the PA/NP Elevate-Derm Conference in Tucson, Arizona.

In this video

Dr. Serota explains that the most important first step when walking into the room with an urticaria patient is deciding whether it's acute (less than six weeks) or chronic (greater than six weeks). There's "no magic to that number" — experts settled on six weeks because beyond that you're unlikely to find an acute trigger and much more likely to be in the autoimmune category. Viral illness is the most common acute trigger, with idiopathic being the second, and once a patient is chronic he counsels them to "stop looking for triggers" and treat it like any other autoimmune disease rather than withdrawing foods.

On workup, he cites a Cleveland Clinic study of 10,000 lab results showing essentially no utility to routine panels like CMP and CBC. Instead he watches for mimics — especially the urticarial phase of bullous pemphigoid in patients 60 and up (biopsy with immunofluorescence), drug-related rashes, and parasitic infection — and considers the chronic urticaria index to confirm an autoimmune pathway. His treatment ladder starts with non-sedating second-generation antihistamines dosed two to four times normal ("plus or minus" H2 blockers and montelukast), then omalizumab for chronic cases, while avoiding systemic steroids that put patients on a flaring "roller coaster."

  • Classify first: acute is under six weeks, chronic is over six weeks — beyond six weeks you're most likely in the autoimmune category and unlikely to find an acute trigger.
  • Viral illness is the most common acute trigger; idiopathic is second. Once chronic, stop hunting for triggers and treat like any autoimmune disease.
  • In a patient 60 and up with new-onset urticaria, ask why it isn't bullous pemphigoid and biopsy with immunofluorescence; also consider drug reactions and GI parasites as mimics.
  • Skip routine lab panels — a 10,000-patient study showed no utility. Consider the chronic urticaria index to confirm the autoimmune pathway and set expectations.
  • Start with high-dose non-sedating second-generation antihistamines, advance to omalizumab for chronic disease, and avoid systemic steroids that guarantee a flare on withdrawal.